已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial

医学 吉非替尼 临床终点 内科学 肿瘤科 临床试验 腺癌 肺癌 表皮生长因子受体 癌症
作者
Zhijie Wang,Ying Cheng,Tongtong An,Hongjun Gao,Kai Wang,Qing Zhou,Yanping Hu,Yong Song,Cuimin Ding,Feng Peng,Li Liang,Yi Hu,Cheng Huang,Caicun Zhou,Yuankai Shi,Li Zhang,Xin Ye,Meizhuo Zhang,Shaokun Chuai,Guanshan Zhu
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:6 (9): 681-690 被引量:216
标识
DOI:10.1016/s2213-2600(18)30264-9
摘要

Background Detection of EGFR mutations in tumour tissue is the gold-standard approach to ascertain if a patient will benefit from treatment with an EGFR tyrosine kinase inhibitor. However, if tissue is scant, another strategy is to use circulating tumour DNA (ctDNA), but this method needs validation in clinical trials. We did a prospective clinical trial to assess ctDNA-based EGFR mutation detection as a selection criterion for patients with lung adenocarcinoma receiving gefitinib as first-line treatment. Methods BENEFIT is a multicentre, single-arm, phase 2 clinical trial at 15 centres in China. Patients aged 18–75 years with stage IV metastatic lung adenocarcinoma and EGFR mutations detected in ctDNA were given oral gefitinib 250 mg once daily as first-line treatment. The primary endpoint was the proportion achieving an objective response. Secondary endpoints included median progression-free survival and safety. Next-generation sequencing (NGS) of a 168-gene panel was used for genetic analysis of baseline blood samples. The primary efficacy analysis was done by intention to treat in patients who had at least one post-baseline tumour assessment. The safety analysis was done in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02282267. Findings Between Dec 25, 2014, and Jan 16, 2016, 426 patients were screened for the trial, of whom 188 with EGFR mutations in ctDNA were enrolled and received gefitinib. 183 patients had one or more post-baseline tumour assessment and were included in the primary efficacy analysis. Median follow-up was 14·5 months (IQR 12·2–16·5). At the time of data cutoff (Jan 31, 2017), 152 patients had progressive disease or had died. The proportion achieving an objective response was 72·1% (95% CI 65·0–78·5). Median progression-free survival was 9·5 months (95% CI 9·07–11·04). Of 167 patients with available blood samples, 147 (88%) showed clearance of EGFR mutations in ctDNA at week 8, and median progression-free survival was longer for these patients than for the 20 patients whose EGFR mutations persisted at week 8 (11·0 months [95% CI 9·43–12·85] vs 2·1 months [1·81–3·65]; hazard ratio [HR] 0·14, 95% CI 0·08–0·23; p<0·0001). From baseline NGS data in 179 patients, we identified three subgroups of patients: those with EGFR mutations only (n=58), those with mutations in EGFR and tumour-suppressor genes (n=97), and those with mutations in EGFR and oncogenes (n=24). Corresponding median progression-free survival in these subgroups was 13·2 months (95% CI 11·5–15·0), 9·3 months (7·6–11·0), and 4·7 months (1·9–9·3), respectively (EGFR mutations only vs mutations in EGFR and tumour-suppressor genes, HR 1·78, 95% CI 1·23–2·58; p=0·002; EGFR mutations only vs mutations in EGFR and oncogenes, 2·66, 1·58–4·49; p=0·0003). The most common grade 3 or 4 adverse events were hepatic function abnormalities (n=24). Serious adverse events were reported in 17 (9%) patients. No unexpected safety events for gefitinib were recorded. Interpretation Detection of EGFR mutations in ctDNA is an effective method to identify patients who might benefit from first-line gefitinib treatment. Further analyses of dynamic alterations of EGFR mutations and accompanying gene aberrances could predict resistance to gefitinib. Funding Guangdong Association of Clinical Trials, AstraZeneca, National Natural Sciences Foundation Key Programme, and National Key Research and Development Programme of China.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
汉堡包的应助被韦智杰采纳,获得10
刚刚
marenmicfena完成签到,获得积分10
1秒前
朱妙彤发布了新的文献求助10
1秒前
JamesPei的应助被养咩咩采纳,获得10
1秒前
冲冲冲冲冲完成签到,获得积分10
2秒前
聪明的小乌龟完成签到,获得积分10
2秒前
万能图书馆的应助被绵绵采纳,获得10
3秒前
虚幻的海白完成签到,获得积分10
3秒前
3秒前
ubless607的应助被huahuahua采纳,获得10
4秒前
香蕉觅云的应助被huahuahua采纳,获得10
4秒前
小二郎的应助被huahuahua采纳,获得10
4秒前
fantasy的应助被huahuahua采纳,获得10
4秒前
嘻嘻哈哈的应助被huahuahua采纳,获得10
4秒前
aajhajkahna的应助被科研通管家采纳,获得10
4秒前
大个的应助被科研通管家采纳,获得10
5秒前
ket的应助被huahuahua采纳,获得10
5秒前
风吹麦浪的应助被科研通管家采纳,获得20
5秒前
syvshc的应助被想活在梦里采纳,获得10
5秒前
飞天大南瓜的应助被huahuahua采纳,获得30
5秒前
我是老大的应助被科研通管家采纳,获得10
5秒前
崔玉坤发布了新的文献求助10
5秒前
烟花的应助被科研通管家采纳,获得10
5秒前
Owen的应助被huahuahua采纳,获得10
5秒前
夹心的应助被科研通管家采纳,获得10
5秒前
Eric的应助被huahuahua采纳,获得10
5秒前
田様的应助被科研通管家采纳,获得10
5秒前
秋风的应助被科研通管家采纳,获得10
5秒前
原神大王的应助被huahuahua采纳,获得10
6秒前
6秒前
英姑的应助被科研通管家采纳,获得10
6秒前
小蘑菇的应助被科研通管家采纳,获得10
6秒前
惊鸿完成签到,获得积分10
6秒前
6秒前
慈祥的大白菜真实的钥匙完成签到,获得积分10
7秒前
lynn完成签到 ,获得积分10
7秒前
DNian关注了科研通微信公众号
7秒前
8秒前
3dunk关注了科研通微信公众号
8秒前
乐观的名发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194415
求助须知:如何正确求助?哪些是违规求助? 9580155
关于积分的说明 21870088
捐赠科研通 7793967
什么是DOI,文献DOI怎么找? 3437647
关于科研通互助平台的介绍 2560986
邀请新用户注册赠送积分活动 2484376